IMUX

#3592
Immunic, Inc. - Common Stock
15.4 0 USD
-0.06%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
15.40
15.40
Jahresspanne
0.51
17.43
Tagesänderung
-5.52%
Monatliche Änderung
+9.76%
6 month change
+1455.56%
Jahresänderung
+1778.05%
Vorheriger Schlusskurs
16.3 0
Open
15.4 0
Tief
15.4 0
Hoch
15.4 0
Volumen
6
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
IMMUNIC, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
IMMUNIC, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
IMMUNIC, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
IMMUNIC, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
IMMUNIC, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
IMMUNIC, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
IMMUNIC, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
IMMUNIC, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
IMMUNIC, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
IMMUNIC, INC. current report, Q2 FY2026
8-K

IMMUNIC, INC. current report, 07 August 2018

Full document

Business Context and Reporting Period

Company: Vital Therapies, Inc. (Note: Request metadata listed "IMMUNIC, INC." but the filing text identifies the registrant as Vital Therapies, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: August 7, 2018
Reporting Period: Quarter ended June 30, 2018
Context: The Company issued a press release announcing an update on key recent developments and financial results for the quarter ended June 30, 2018. A conference call was held on August 7, 2018, to discuss these results.

Key Financial Metrics

The provided filing text (Form 8-K) serves as a notification of the press release and does not contain specific numerical data. The following metrics are not present in the source text:

  • Revenue: Not provided in filing text.
  • Profit/Loss: Not provided in filing text.
  • Cash Flow: Not provided in filing text.
  • Margins: Not provided in filing text.
  • Debt and Liquidity: Not provided in filing text.

Note: Specific financial figures are contained in the attached Exhibit 99.1 (Press Release), which is referenced but not included in the input text.

Material Changes

The filing text does not provide specific comparative data or material changes versus the prior comparable period. It only states that an update on key recent developments and financial results was issued.

Guidance, Outlook, and Risks

Management Commentary: The Company provided a corporate update and discussed financial results for the quarter ended June 30, 2018, via a press release and conference call.
Guidance and Outlook: No specific forward-looking guidance or outlook figures are present in the filing text.
Risks and Contingencies: No specific risks or contingencies are detailed in the filing text.
Unusual Items: None identified in the filing text.

Investor Verification Checklist

  • Verify the specific financial results (revenue, net loss, cash position) by reviewing the full text of the Press Release (Exhibit 99.1) referenced in this filing.
  • Confirm the details of the "key recent developments" mentioned in the corporate update, as these are not detailed in the 8-K body.
  • Review the conference call transcript (if available) for management's detailed commentary on the quarter ended June 30, 2018.
  • Ensure the correct company name is used for analysis (Vital Therapies, Inc.), noting the discrepancy with the request metadata.

Nachrichten